TZTao Zeng

Tao Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tao Zeng has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Haojie Peng

    Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

    2 shared publications
  • Xinxin Chen

    Department of breast surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Baijin Xia

    Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou, Guangdong, China

    1 shared publication
  • Dexun Sun

    Department of Gastrointestinal (hernia) Surgery, Sanya Central Hospital (Third People’s Hospital of Hainan Province), Sanya, Hainan, China

    1 shared publication
  • Fei Yu

    Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China

    1 shared publication
  • Fenmei Liang

    Department of Breast Surgery, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China

    1 shared publication

Latest Publications

  • Open Access

    Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study

    by Fenmei Liang, Guanhua Lu, Dexun Sun, Pangzhou Chen, Yichuan Shi, Haojie Peng, Tao Zeng, Meilin Hu, Kaili Zhu, Kai Qiu, et al.

    Background: Taxane-associated acute pain syndrome (T-APS) is a frequent adverse effect in breast cancer patients undergoing nab-paclitaxel, affecting treatment adherence and quality of life (QoL). We analyzed the effectiveness of preventative celecoxib on T-APS among these patients. Methods: This non-randomized controlled trial included 270 breast cancer patients receiving nab-paclitaxel who experienced musculoskeletal pain during the first cycle. Subjects were assigned to receive celecoxib (200 mg, administered on Days 1–7) or a placebo. The main outcome measured was the overall incidence of severe T-APS (>5 on a 0–10 scale) during cycles 2–4. Secondary endpoints included the incidence, severity, and duration of T-APS (assessed by the Brief Pain Inventory scale); QoL; peripheral nerve function; and adverse events. Results: The overall incidence of severe T-APS was 10.2% in the celecoxib group and 50.0% in the placebo group during cycles 2–4 ( P < 0.001). Mean FACT-B subscale scores were significantly higher in the celecoxib group (101.62, 95% CI: 99.70–103.53; 105.59, 95% CI: 103.57–107.61; and 108.02, 95%CI: 106.18–109.85) than the placebo group (99.02, 95% CI: 97.29–100.76; 99.80, 95% CI: 98.03–101.57; and 99.10, 95% CI: 97.39–100.81) ( P < 0.05). QoL on EORTC QLQ-C30 was also better in the celecoxib group, except for appetite loss, fatigue, and insomnia ( P < 0.05). Following four cycles, the mean scores on the FACT-Ntx subscale in the celecoxib group remained higher (34.10, 95% CI: 33.29–34.91 vs 32.25, 95% CI: 31.63–32.88) ( P < 0.01). Additionally, the incidence of peripheral neuropathy at grade 1 or higher in CTCAE 5.0 was reduced in the celecoxib group (36.7% vs 63.8%, P < 0.001). Conclusion: Preventative celecoxib significantly reduced the incidence of severe T-APS and improved QoL in breast cancer patients.


  • Open Access

    ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis

    by Lixue Cao, Haojie Peng, Yanzhen Chen, Baijin Xia, Tao Zeng, Jialing Guo, Fei Yu, Haiyan Ye, Hui Zhang, Xinxin Chen

    Background The failure of conventional therapies and the propensity for recurrence and metastasis make triple-negative breast cancer (TNBC) a formidable challenge with grim prognoses and diminished survival rates. Immunotherapy, including immune checkpoint blockade and chimeric antigen receptor (CAR)-T cell therapy, presents innovative and potentially more effective strategies for addressing TNBC. Within this context, the inducible costimulator (ICOS), a member of the CTLA4/CD28 family, plays a crucial role in regulating immune responses and T-cell differentiation by binding to its ligand ICOSL. However, the impact of the ICOS/ICOSL axis on cancer varies. Methods In this study, immunohistochemistry was conducted to examine the expression level of ICOSL in TNBC tumor tissues. We developed ICOS-enhanced B7H3-CAR-T cells (ICOS-B7H3-CAR) using the third-generation CAR-T cell technology, which featured magnified ICOS expression and targeted the B7H3 antigen. Xenograft and metastasis models of TNBC were conducted to examine the cytotoxicity and durability of CAR-T cells in tumors. Overexpression and CRISPR/Cas9-mediated knockout (KO) techniques were employed to regulate the expression of ICOSL on TNBC cell lines. Results Notably, we observed elevated ICOSL expression in TNBC tumor tissues, which correlated with poor survival prognosis in patients with TNBC. Compared with conventional B7H3-CAR-T cells, ICOS-B7H3-CAR-T cells significantly inhibited the tumor growth of TNBC cells both in vitro and in vivo, accompanied by increased secretion of cytokines such as interferon gamma and tumor necrosis factor alpha. Furthermore, the in vivo experiments illustrated that ICOS-B7H3-CAR-T cells exhibited prolonged antitumor activity and could effectively eradicate metastases in a TNBC metastasis model, consequently extending survival. Importantly, manipulating the expression of ICOSL on TNBC cells through overexpression or KO significantly influenced the function of ICOS-B7H3-CAR-T cells. This suggests that the level of ICOSL expression on TNBC cells is critical for enhancing the potent antitumor effects of ICOS-B7H3-CAR-T cells. Conclusion Overall, our study highlights the potential clinical application of ICOS as a promising strategy for combating TNBC recurrence and metastasis.